Conferencia de resultados del T2 de 2026 de HeartBeam (BEAT): presentación ante la FDA, menor consumo de efectivo y lanzamiento comercial
La conferencia de resultados del segundo trimestre de 2026 de HeartBeam abordó una pérdida neta de 5 millones de dólares, un menor consumo de efectivo, avances ante la FDA y un despliegue comercial inicial en cuatro mercados de EE. UU.
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.